MedPath

NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES

๐Ÿ‡บ๐Ÿ‡ธUnited States
Ownership
-
Employees
-
Market Cap
-
Website

A Study to Test the Safety, Tolerance, and Metabolism of Abacavir (1592U89, ABC) With Standard Zidovudine (ZDV) Therapy in Newborn Infants Born to HIV-1 Infected Women

Phase 1
Completed
Conditions
HIV Infections
First Posted Date
2001-08-31
Last Posted Date
2021-10-28
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
60
Registration Number
NCT00000864
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Univ. of Florida Jacksonville NICHD CRS, Jacksonville, Florida, United States

๐Ÿ‡บ๐Ÿ‡ธ

Bronx-Lebanon Hosp. IMPAACT CRS, Bronx, New York, United States

๐Ÿ‡ต๐Ÿ‡ท

San Juan City Hosp. PR NICHD CRS, San Juan, Puerto Rico

and more 10 locations

Phase I Safety and Immunogenicity Trial of Vaccinia-HIV Envelope Recombinant Vaccine (HIVAC-1e) in Combination With Soluble Recombinant Envelope Vaccine (gp160; VaxSyn)

Phase 1
Completed
Conditions
HIV Infections
First Posted Date
2001-08-31
Last Posted Date
2021-10-27
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
35
Registration Number
NCT00000630
Locations
๐Ÿ‡บ๐Ÿ‡ธ

UW - Seattle AVEG, Seattle, Washington, United States

๐Ÿ‡บ๐Ÿ‡ธ

Vanderbilt Univ. Hosp. AVEG, Nashville, Tennessee, United States

ALVAC-HIV vCP1452 Alone and Combined With MN rgp120

Phase 2
Completed
Conditions
HIV Seronegativity
HIV Infections
Interventions
Biological: ALVAC(2)120(B,MN)GNP (vCP1452)
Biological: ALVAC(2)120(B,MN)GNP (vCP1452) placebo
Biological: MN rgp120/HIV-1 placebo
Biological: MN rgp120/HIV-1
First Posted Date
2001-08-31
Last Posted Date
2021-10-14
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
160
Registration Number
NCT00011037
Locations
๐Ÿ‡ต๐Ÿ‡ช

Barranco CRS, Lima, Peru

๐Ÿ‡ง๐Ÿ‡ท

Projeto Praรงa Onze/Hesfa Crs, Rio de Janeiro, Brazil

๐Ÿ‡ญ๐Ÿ‡น

Les Centres GHESKIO CRS, Port-au-Prince, Haiti

and more 1 locations

A Study of Zidovudine in the Prevention of HIV Infection in Individuals Exposed to the Virus

Not Applicable
Completed
Conditions
HIV Infections
First Posted Date
2001-08-31
Last Posted Date
2016-11-06
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Registration Number
NCT00000993
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Glaxo Wellcome Inc, Research Triangle Park, North Carolina, United States

A Test of Behavioral Intervention for Women at High Risk for HIV Infection

Completed
Conditions
HIV Infections
First Posted Date
2001-08-31
Last Posted Date
2016-10-31
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
180
Registration Number
NCT00006440
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Anne Colletti, Cambridge, Massachusetts, United States

Pediatric Kidney Transplant Without Calcineurin Inhibitors

Not Applicable
Completed
Conditions
End-Stage Renal Disease
Interventions
First Posted Date
2001-08-31
Last Posted Date
2016-10-21
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
35
Registration Number
NCT00023231
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Lauren Schenker, Rockville, Maryland, United States

Effect of a Change in HIV Therapy on Liver Steatosis, Inflammation, and Fibrosis

Not Applicable
Withdrawn
Conditions
HIV Infections
Hepatitis C
First Posted Date
2001-08-31
Last Posted Date
2015-03-09
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Registration Number
NCT00023218
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Univ of Hawaii, Honolulu, Hawaii, United States

๐Ÿ‡บ๐Ÿ‡ธ

Beth Israel Med Ctr, New York, New York, United States

๐Ÿ‡บ๐Ÿ‡ธ

Tripler Army Med Ctr, Tripler AMC, Hawaii, United States

A Study of Patients Who Recently Have Been Infected With HIV

Withdrawn
Conditions
HIV Infections
First Posted Date
2001-08-31
Last Posted Date
2015-03-09
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Registration Number
NCT00006415

Effectiveness of Interleukin-2 (IL-2) Plus Anti-HIV Therapy in HIV-Positive Patients

Not Applicable
Completed
Conditions
HIV Infections
Interventions
First Posted Date
2001-08-31
Last Posted Date
2015-05-15
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
42
Registration Number
NCT00001131
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Johns Hopkins Hosp, Baltimore, Maryland, United States

A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial of the Safety and Efficacy of Ceftriaxone and Doxycycline in the Treatment of Patients With Seropositive Chronic Lyme Disease

Phase 3
Completed
Conditions
Lyme Disease
First Posted Date
2001-08-31
Last Posted Date
2010-08-27
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
194
Registration Number
NCT00001101
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Mark Klempner, Boston, Massachusetts, United States

ยฉ Copyright 2025. All Rights Reserved by MedPath